Regeneron Pharmaceuticals
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +18.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 2.2% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 6 of 6 factors. Missing data is not a zero score.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 20.4x | Better than 42% |
| Forward P/E | 12.9x | Better than 64% |
| Price / Sales | 5.8x | Better than 19% |
| P/E vs own 5-yr range | 74th pctl | Better than 33% |
Growth C+
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 5.6% | Better than 49% |
| Net income CAGR (3Y) | 1.3% | Better than 43% |
| Free cash flow CAGR (3Y) | 3.5% | Better than 43% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 85.4% | Better than 94% |
| Operating margin | 25.8% | Better than 85% |
| Net margin | 31.4% | Better than 91% |
| Return on equity | 14.9% | Better than 68% |
| Return on invested capital | 11.9% | Better than 75% |
Momentum A
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 10.4% | Better than 90% |
| 6-month return | 44.3% | Better than 94% |
| 12-month return (ex latest month) | 8.8% | Better than 44% |
| Distance below 52-week high | 7.1% | Better than 91% |
Financial Health A
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.1x | Better than 82% |
| Debt to assets | 6.7% | Better than 76% |
| Interest coverage | 120.4x | Better than 94% |
| Free cash flow / net income | 83.6% | Better than 28% |
Analyst View C-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 69.6% | Better than 48% |
| Upside to average target | 5.0% | Better than 8% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 922.40
- Open
- 935.80
- Day range
- 916.66 - 948.42
- Avg price
- 926.22
- Volume
- 878.26K
- Turnover
- 813.46M
- Turnover ratei
- 0.88%
- Volume ratioi
- 1.01
- Amplitudei
- 3.44%
- 52-week rangei
- 590.23 - 990.72
Valuation
- P/Ei
- 22.20
- P/E (TTM)i
- 20.35
- P/Bi
- 2.84
- EPSi
- 41.48
- Book value / shi
- 323.82
- Net profit
- 4.29B
- Net assets
- 33.50B
Share structure
- Market cap
- 95.24B
- Float capi
- 91.57B
- Shares out
- 103.45M
- Float sharesi
- 99.46M
Dividend & listing
- Div yield (TTM)i
- 0.40%
- Dividend (TTM)
- 3.70
- Listing date
- 1970-01-01
7.1% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-20.63M net over the window
Short interest
- Shares short
- 2.22M
- % of floati
- 2.15%
- Days to coveri
- 2.73
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Regeneron Pharmaceuticals (REGN)?
Regeneron Pharmaceuticals last traded at 920.69. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Regeneron Pharmaceuticals's market cap?
About 95.24B.
What is the P/E ratio of Regeneron Pharmaceuticals?
The trailing twelve-month P/E is 20.35, above its own 5-year average of 18.34 — toward the top of its historical range (73.94% percentile). See the Valuation tab for the full history.
Does Regeneron Pharmaceuticals pay a dividend?
Yes. The trailing dividend yield is 0.40%. See the Dividends tab for the full payment history.
Is Regeneron Pharmaceuticals a buy according to analysts?
The consensus of 23 analysts is a Buy rating, with an average 12-month price target of 959.57, which implies 4.2% upside from the current price. This is not investment advice.
What is Regeneron Pharmaceuticals's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Regeneron Pharmaceuticals a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments